Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

CAREDX, INC.

Filed by TODD STRATEGY GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-11-01 06:26:09 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Termination
Posted
Oct 20, 2026
Income
$60,000.00
Expenses
Not reported
Filing UUID
e8da5266-4127-400d-8af3-61f53e8617ed
Termination date
May 31, 2026

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.

Literal federal measure citations: H.R.5269

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.